Membranoproliferative glomerulonephritis screening: Difference between revisions
Created page with "==Overview== The entity, MPGN is a pathological definition, though it has some laboratory findings to guide to this diagnosis. till now there is not specific screening protoco..." |
Aditya Ganti (talk | contribs) |
||
(5 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Membranoproliferative glomerulonephritis}} | |||
{{CMG}} ; {{AE}} {{JSS}} | |||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for MPN. | |||
==Screening== | |||
There is insufficient evidence to recommend routine screening for MPN. | |||
==References== | |||
{{reflist|2}} |
Latest revision as of 20:07, 6 August 2018
Membranoproliferative glomerulonephritis Microchapters |
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Membranoproliferative glomerulonephritis screening On the Web |
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis screening |
Membranoproliferative glomerulonephritis screening in the news |
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
Risk calculators and risk factors for Membranoproliferative glomerulonephritis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for MPN.
Screening
There is insufficient evidence to recommend routine screening for MPN.